Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC). The aim of this trial was to evaluate the efficacy and safety of this combination in MCRC as second-line treatment after failure of 24-h inf...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2005
|
| In: |
Anti-cancer drugs
Year: 2005, Jahrgang: 16, Heft: 1, Pages: 39-45 |
| ISSN: | 1473-5741 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2005/01000/Irinotecan_and_capecitabine_as_second_line.5.aspx
|
| Verfasserangaben: | Ralf-Dieter Hofheinz, Ulrike Gnad-Vogt, Axel Wein, Susanne Saussele, Sebastian Kreil, Lothar Pilz, Rüdiger Hehlmann and Andreas Hochhaus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1801655243 | ||
| 003 | DE-627 | ||
| 005 | 20230426073510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220512s2005 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1801655243 | ||
| 035 | |a (DE-599)KXP1801655243 | ||
| 035 | |a (OCoLC)1341459491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer |b a phase II study |c Ralf-Dieter Hofheinz, Ulrike Gnad-Vogt, Axel Wein, Susanne Saussele, Sebastian Kreil, Lothar Pilz, Rüdiger Hehlmann and Andreas Hochhaus |
| 264 | 1 | |c 2005 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.05.2022 | ||
| 520 | |a The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC). The aim of this trial was to evaluate the efficacy and safety of this combination in MCRC as second-line treatment after failure of 24-h infusional 5-fluorouracil (5-FU24h) and folinic acid (FA). Patients pre-treated with 5-FU24h/FA were recruited at two institutions to receive 6×weekly irinotecan 70 mg/m2 and capecitabine (1000 mg/m2 b.i.d. days 1-14 and 22-35). Courses were repeated on day 50. In elderly patients (>65 years) a 20% dose reduction of both drugs was scheduled. Twenty-eight patients [M/F 20/8; median age 65 years (range 44-79); median ECOG score 1] were enrolled. The most frequent sites of metastases were liver, n=20, lymph nodes and lungs, n=10, respectively. Half of the patients had two or more metastatic sites. A total of 71 treatment courses (median 2, range 1-8) were administered. Main toxicities [worst per patient (%); CTC grade 1/2/3/4] were: anaemias 18/14/-/-; leukocytopenia 11/21/-/-; thrombocytopenia 11/-/-/-; diarrhea 18/36/21/-; nausea/vomiting 43/29/4/-; mucositis 4/11/-/-; alopecia 7/25/-/-; hand-foot syndrome 7/21/-/-; fatigue 14/14/-/-; renal insufficiency (caused by diarrhea and exsiccosis) -/-/-/7. Dose intensity in the first course was [median/mean (%)]: irinotecan 92/83; capecitabine 88/82. Twenty-three patients are evaluable for response analysis (five did not complete the first course): three patients showed partial remissions (13%) and 11 patients had stable disease (48%). Median time to progression was 3.0 months for the total population (range 1.4-17.3) and 6.5 months for responders (partial response plus no change). Seventy-four percent of the patients received a third-line therapy. Overall survival was 15.7 months calculated from the start of study treatment. Second-line therapy with irinotecan and capecitabine yielded a tumor control in 61% of patients with MCRC. Efficacy and toxicity data are comparable to 5-FU/irinotecan combinations, although the likelihood of severe diarrhea appears to be higher with capecitabine/irinotecan. | ||
| 700 | 1 | |a Gnad-Vogt, Ulrike |e VerfasserIn |0 (DE-588)1257363972 |0 (DE-627)1801662991 |4 aut | |
| 700 | 1 | |a Wein, Axel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 700 | 1 | |a Kreil, Sebastian |d 1972- |e VerfasserIn |0 (DE-588)1072240564 |0 (DE-627)827077742 |0 (DE-576)433714093 |4 aut | |
| 700 | 1 | |a Pilz, Lothar R. |d 1954- |e VerfasserIn |0 (DE-588)1036758621 |0 (DE-627)751686107 |0 (DE-576)38680799X |4 aut | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 700 | 1 | |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer drugs |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1990 |g 16(2005), 1, Seite 39-45 |h Online-Ressource |w (DE-627)320649652 |w (DE-600)2025803-3 |w (DE-576)094502161 |x 1473-5741 |7 nnas |a Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer a phase II study |
| 773 | 1 | 8 | |g volume:16 |g year:2005 |g number:1 |g pages:39-45 |g extent:7 |a Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer a phase II study |
| 856 | 4 | 0 | |u https://journals.lww.com/anti-cancerdrugs/Fulltext/2005/01000/Irinotecan_and_capecitabine_as_second_line.5.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220512 | ||
| 993 | |a Article | ||
| 994 | |a 2005 | ||
| 998 | |g 1107039339 |a Hochhaus, Andreas |m 1107039339:Hochhaus, Andreas |d 60000 |d 61200 |e 60000PH1107039339 |e 61200PH1107039339 |k 0/60000/ |k 1/60000/61200/ |p 8 |y j | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 998 | |g 1036758621 |a Pilz, Lothar R. |m 1036758621:Pilz, Lothar R. |d 60000 |e 60000PP1036758621 |k 0/60000/ |p 6 | ||
| 998 | |g 1072240564 |a Kreil, Sebastian |m 1072240564:Kreil, Sebastian |d 60000 |d 61200 |e 60000PK1072240564 |e 61200PK1072240564 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 1257363972 |a Gnad-Vogt, Ulrike |m 1257363972:Gnad-Vogt, Ulrike |d 60000 |d 61200 |e 60000PG1257363972 |e 61200PG1257363972 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1801655243 |e 4133199502 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"7 S."}],"id":{"eki":["1801655243"]},"title":[{"subtitle":"a phase II study","title":"Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer","title_sort":"Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2005","dateIssuedKey":"2005"}],"relHost":[{"disp":"Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer a phase II studyAnti-cancer drugs","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1990 -"],"note":["Gesehen am 17.10.05"],"part":{"text":"16(2005), 1, Seite 39-45","pages":"39-45","extent":"7","issue":"1","year":"2005","volume":"16"},"language":["eng"],"origin":[{"publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320649652"],"issn":["1473-5741"],"zdb":["2025803-3"]},"title":[{"title":"Anti-cancer drugs","title_sort":"Anti-cancer drugs"}],"recId":"320649652"}],"language":["eng"],"name":{"displayForm":["Ralf-Dieter Hofheinz, Ulrike Gnad-Vogt, Axel Wein, Susanne Saussele, Sebastian Kreil, Lothar Pilz, Rüdiger Hehlmann and Andreas Hochhaus"]},"note":["Gesehen am 12.05.2022"],"person":[{"given":"Ralf-Dieter","display":"Hofheinz, Ralf-Dieter","role":"aut","family":"Hofheinz"},{"display":"Gnad-Vogt, Ulrike","given":"Ulrike","family":"Gnad-Vogt","role":"aut"},{"family":"Wein","role":"aut","display":"Wein, Axel","given":"Axel"},{"family":"Saußele","role":"aut","given":"Susanne","display":"Saußele, Susanne"},{"role":"aut","family":"Kreil","given":"Sebastian","display":"Kreil, Sebastian"},{"given":"Lothar R.","display":"Pilz, Lothar R.","family":"Pilz","role":"aut"},{"family":"Hehlmann","role":"aut","given":"Rüdiger","display":"Hehlmann, Rüdiger"},{"family":"Hochhaus","role":"aut","display":"Hochhaus, Andreas","given":"Andreas"}],"recId":"1801655243"} | ||
| SRT | |a HOFHEINZRAIRINOTECAN2005 | ||